Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Mol Cancer Ther. 2016 Jul 29;15(10):2302–2313. doi: 10.1158/1535-7163.MCT-15-0801

Figure 1.

Figure 1

Imatinib and CNDAC are synergistic in HCT116 cells, regardless of p53 status. HCT116 cells with wild type p53 and p53 KO were pretreated with imatinib (5 – 50 µM) for 2 hours before co-incubation with CNDAC (0.05 – 0.4 µM). Cells were washed after 24 hours and incubated in medium with imatinib added at the same concentrations until colonies were fixed. A, comparison of clonogenicity of p53 wild type and p53 KO after treatment with imatinib alone vs imatinib-CNDAC combination at a fixed ratio (200:1), representative of 3 independent experiments (ratios 200:1 or 50:1). B, median effect analysis algebraic estimate of imatinib and CNDAC combination (ratio 200:1), representative of 3 independent experiments. C, values of combination index (CI) at 50%, 75% and 90% clonogenic inhibition and dose reduction index (DRI) at 90% clonogenic inhibition (mean ± S.D.).